{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T17:17:19Z","timestamp":1768670239089,"version":"3.49.0"},"reference-count":40,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032569","name":"Janssen Korea Ltd.","doi-asserted-by":"crossref","award":["CNTO1959PSO4003"],"award-info":[{"award-number":["CNTO1959PSO4003"]}],"id":[{"id":"10.13039\/100032569","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: This study aimed to identify the baseline characteristics predictive of Psoriasis Area and Sensitivity Index (PASI) 90 response to guselkumab and assess treatment effectiveness outcomes for PASI 90 responders and PASI 90 non-responders. Methods: This post hoc analysis used data from a prospective, multicenter, observational study of guselkumab in Korean patients with moderate-to-severe psoriasis conducted between February 2019 and March 2022. Stepwise logistic regression analysis was used to identify baseline characteristics predictive of PASI 90 response. Results: Of 339 patients, 245 (72.3%) week-28 PASI 90 responders and 94 (27.7%) non-responders were identified. Baseline characteristics significantly predictive of PASI 90 response in multivariate logistic regression were absence of family history of psoriasis (odds ratio [OR]: 0.35; p = 0.0266), higher PASI score (OR: 1.22; p = 0.0006), higher body surface area of psoriasis involvement (OR: 0.95; p = 0.0127), prior phototherapy use (OR: 2.44; p = 0.0108), and reduced concomitant topical agent use (OR: 0.41; p = 0.0044). More PASI 90 responders versus non-responders achieved absolute PASI score \u2264 2 by week 44 (95.8% vs. 67.5%) and Dermatology Life Quality Index scores of 0 or 1 by week 28 (72.2% vs. 34.0%). Conclusions: Guselkumab PASI 90 responders had unique baseline characteristics that may predict positive treatment outcomes.<\/jats:p>","DOI":"10.3390\/jcm15020704","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:31:41Z","timestamp":1768480301000},"page":"704","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors Predicting Guselkumab Treatment Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of Korean Real-World Data"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-2479","authenticated-orcid":false,"given":"Young Bok","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Dermatology, Uijeongbu St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu 11765, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bong Seok","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chosun University College of Medicine, Gwangju 61453, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miri","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yeouido St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 07345, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moo Kyu","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dongguk University College of Medicine, Gyeongju 38067, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Woong","family":"Youn","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Yeoun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul 05355, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga-Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5315-6031","authenticated-orcid":false,"given":"Kwang Ho","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihye","family":"An","sequence":"additional","affiliation":[{"name":"Medical Affairs, Johnson & Johnson, Seoul 04386, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0772-6360","authenticated-orcid":false,"given":"Youngdoe","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Affairs, Johnson & Johnson, Seoul 04386, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Joong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-2400","authenticated-orcid":false,"given":"Dong Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13496, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Wook","family":"Son","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Korea University Ansan Hospital, 516, Gojan 1-dong, Danwon-gu, Ansan 15355, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"ref_1","first-page":"84","article-title":"Management of plaque psoriasis: A review and comparison of IL-23 inhibitors","volume":"8","author":"Bolick","year":"2020","journal-title":"EMJ Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/jdv.18474","article-title":"Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: Age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator\u2019s Global Assessment scores predict complete skin clearance","volume":"36","author":"Reich","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","first-page":"13030","article-title":"Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity","volume":"21","author":"Korman","year":"2015","journal-title":"Dermatol. Online J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s13555-022-00695-0","article-title":"Impact of psoriatic disease on quality of life: Interim results of a global survey","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bjd.16332","article-title":"A multidimensional assessment of the burden of psoriasis: Results from a multinational dermatologist and patient survey","volume":"179","author":"Griffiths","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.36849\/JDD.2020.4957","article-title":"Importance of complete skin clearance in psoriasis as a treatment goal: Implications for patient-reported outcomes","volume":"19","author":"Blauvelt","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of gusel-kumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/archdermatol.2010.384","article-title":"Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: Efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial","volume":"147","author":"Leonardi","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014Results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: From keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"i634","DOI":"10.1093\/ecco-jcc\/jjac190.0634","article-title":"P504 guselkumab, an IL-23p19 subunit\u2013specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells","volume":"17","author":"Atreya","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/annrheumdis-2023-eular.826","article-title":"POS1531 guselkumab, an IL-23P19 subunit\u2013specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells","volume":"82","author":"McGonagle","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","unstructured":"European Medicines Agency (EMA) (2025, February 06). Tremfya Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tremfya-epar-product-information_en.pdf."},{"key":"ref_16","unstructured":"Ministry of Food and Drug Safety (2025, February 06). Trempier Prefilled Syringe (Guselkumab, Genetically Modified). Available online: https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetailCache?cacheSeq=201801604aupdateTs2023-12-26%2014:24:05.0b."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/1346-8138.17255","article-title":"Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20-week interim analysis of a postmarketing surveillance study","volume":"51","author":"Tada","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_18","unstructured":"United States Food and Drug Administration (2025, February 06). TREMFYA (Guselkumab) Injection, for Subcutaneous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761061s000lbl.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bjd.20568","article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: Results from VOYAGE 1 and VOYAGE 2","volume":"185","author":"Reich","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/ijd.15784","article-title":"Super responders to guselkumab treatment in moderate-to-severe psoriasis: A real clinical practice pilot series","volume":"61","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/JID.2015.378","article-title":"Molecular phenotyping small (Asian) versus large (Western) plaque psoriasis shows common activation of IL-17 pathway genes but different regulatory gene sets","volume":"136","author":"Kim","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/1346-8138.17757","article-title":"Effectiveness and safety of guselkumab in patients with moderate-to-severe plaque psoriasis in real-world practice in Korea: A prospective, multicenter, observational, postmarketing surveillance study","volume":"52","author":"Shin","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2331782","DOI":"10.1080\/09546634.2024.2331782","article-title":"Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: A real-life cohort study on the effectiveness and drug survival over one-year","volume":"35","author":"Liu","year":"2024","journal-title":"J. Dermatolog. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"adv00579","DOI":"10.2340\/actadv.v101.351","article-title":"Predictors of response to biologics in patients with moderate-to-severe psoriasis: A Danish nationwide cohort study","volume":"101","author":"Schwarz","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s13555-021-00679-6","article-title":"Efficacy of risankizumab versus secukinumab in patients with moderate-to-severe psoriasis: Subgroup analysis from the IMMerge study","volume":"12","author":"Crowley","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1111\/jdv.16568","article-title":"A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)","volume":"34","author":"Seneschal","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_28","first-page":"e15488","article-title":"Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study","volume":"35","author":"Caldarola","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_29","first-page":"e15489","article-title":"Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study","volume":"35","author":"Caldarola","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_30","first-page":"e15670","article-title":"Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study","volume":"35","author":"Mastorino","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jdv.18825","article-title":"Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104\u2009weeks","volume":"37","author":"Rompoti","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2024119","DOI":"10.5826\/dpc.1402a119","article-title":"A real-life 208 week single-centred, register-based retrospective study assessing secukinumab survival and long-term efficacy and safety among Greek patients with moderate to severe plaque psoriasis, including difficult-to-treat manifestations such as genitals and scalp","volume":"14","author":"Kyrmanidou","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/exd.14731","article-title":"\u201cSuper-responders\u201d at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors","volume":"32","author":"Mastorino","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s13555-021-00654-1","article-title":"Nail involvement as a predictor of differential treatment effects of secukinumab versus ustekinumab in patients with moderate to severe psoriasis","volume":"12","author":"Conrad","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"adv40556","DOI":"10.2340\/actadv.v104.40556","article-title":"Identifying predictors of PASI100 responses up to month 12 in patients with moderate-to-severe psoriasis receiving biologics in the Psoriasis Study of Health Outcomes (PSoHO)","volume":"104","author":"Armstrong","year":"2024","journal-title":"Acta Derm. Venereol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Reich","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"928","DOI":"10.25259\/IJDVL_308_2022","article-title":"Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea","volume":"89","author":"Shin","year":"2023","journal-title":"Indian. J. Dermatol. Venereol. Leprol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/PTT.S478352","article-title":"The association between patient-reported disease burden and treatment switching in patients with plaque psoriasis treated with nonbiologic systemic therapy","volume":"14","author":"Patel","year":"2024","journal-title":"Psoriasis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","article-title":"Clinical meaningfulness of complete skin clearance in psoriasis","volume":"75","author":"Strober","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/jdv.14865","article-title":"The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: Analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study)","volume":"32","author":"Youn","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/704\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T05:58:03Z","timestamp":1768629483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15020704"],"URL":"https:\/\/doi.org\/10.3390\/jcm15020704","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]}}}